PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aprea Therapeutics, Inc. (APRE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS03836J1025
CUSIP03836J102
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$22.87M
EPS$12.31
PE Ratio0.50
Revenue (TTM)$569.16K
EBITDA (TTM)-$14.45M
Year Range$2.78 - $8.85
Target Price$15.00
Short %2.23%
Short Ratio4.25

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with APRE

Aprea Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aprea Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%OctoberNovemberDecember2024FebruaryMarch
-98.37%
80.52%
APRE (Aprea Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aprea Therapeutics, Inc. had a return of 42.34% year-to-date (YTD) and 47.03% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date42.34%10.16%
1 month-7.98%3.47%
6 months64.52%22.20%
1 year47.03%30.45%
5 years (annualized)N/A13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202410.00%63.64%
202319.35%12.61%-19.36%8.33%29.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Aprea Therapeutics, Inc. (APRE) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
APRE
Aprea Therapeutics, Inc.
0.52
^GSPC
S&P 500
2.79

Sharpe Ratio

The current Aprea Therapeutics, Inc. Sharpe ratio is 0.52. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
0.52
2.79
APRE (Aprea Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aprea Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-99.32%
0
APRE (Aprea Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aprea Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aprea Therapeutics, Inc. was 99.71%, occurring on Jul 10, 2023. The portfolio has not yet recovered.

The current Aprea Therapeutics, Inc. drawdown is 99.32%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.71%Dec 30, 2019887Jul 10, 2023
-24.77%Nov 20, 20195Nov 26, 20199Dec 10, 201914
-17.45%Dec 13, 20194Dec 18, 20194Dec 24, 20198
-8.92%Oct 22, 20197Oct 30, 201911Nov 14, 201918
-7.61%Oct 4, 20193Oct 8, 20198Oct 18, 201911

Volatility

Volatility Chart

The current Aprea Therapeutics, Inc. volatility is 34.23%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%OctoberNovemberDecember2024FebruaryMarch
34.23%
2.80%
APRE (Aprea Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aprea Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items